PARP inhibitor may be effective against some triple-negative breast cancers lacking BRCA mutations

The investigational PARP inhibitor talazoparib caused regression of patient-derived xenografts (PDXs) of triple-negative breast cancers (TNBC) that had BRCA mutations and also those that did not have BRCA mutations but had other alterations in DNA...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2z2tpkn
via IFTTT